Skip to main content
. Author manuscript; available in PMC: 2017 Aug 15.
Published in final edited form as: J Immunol. 2016 Jul 8;197(4):1425–1434. doi: 10.4049/jimmunol.1600264

Figure 6. Treatment with α-IL-5 reduces eosinophil numbers and disease severity in G2A−/− mice.

Figure 6

Mice were treated with α-IL-5 clone TRFK5 or isotype control antibody as described in Experimental Procedures. A, Total eosinophils at day 6 were determined as described in Fig.2. B, colon length normalized to initial body weight and C, disease activity (DAI) determined over the timecourse of DSS exposure (left) and in an expanded representation for day 6 after DSS exposure (right). Dotted line represents colon length per initial body weight from water control animals (B) or maximum DAI score (C). Data represents mean ± SEM; n=10, **p<0.01 compared to WT isotype, WT α-IL-5 and G2A−/− α-IL-5; *p<0.05 compared to G2A−/− α-IL-5 or WT isotype; #p<0.05 compared to WT isotype, G2A−/− isotype and G2A−/− α-IL-5; †p<0.01 compared to WT isotype or G2A−/− α-IL-5.